Company: CERO
Filing Date: 2025-12-05
Form Type: S-1
Source: 0001213900-25-118817
Chunk: 362

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-12-05
Form: S-1
Chunk 362
---
 received net proceeds of $ 320,801. On September 15, 2025, the 30th day following the effective date of the registration statement to be filed pursuant to the Registration Rights Agreement, the conversion price of Series D Preferred Stock was lowered to from $ 15.60to $ 5.36, the Series D Adjustment Price. In connection with this down round triggering event, during the threeand nine months ended September 30, 2025, the Company recorded a deemed dividend of $ 6,649,828, which represents the fair value of excess common stock convertible and issuable to the preferred shareholders upon the occurrence of the initial trigger event based on a per common share price of $ 5.43, the effect of which was an increase in the net loss attributable to common shareholders in the accompanying condensed consolidated statement of operations for the three and nine months ended September 30, 2025. During the three months ended September 30, 2025, 200shares of Series D Preferred Stock were converted into 37,314shares of Common Stock. The conversion ratios were at the Series D Adjustment Price. As of September 30, 2025, there were 9,800remaining shares of Series D Preferred Stock, which were convertible into approximately 1,828,358shares of Common Stock. Purchase of Common Stock by Keystone Capital Partners under the Equity Line of Credit (“ELOC”) On February 14, 2024, in conjunction with, and as a condition to the closing of the Series A PIPE Financing, the Company entered into a common stock purchase agreement with Keystone Capital Partners, L.P. (“Keystone”), pursuant to which we may sell and issue, and Keystone is obligated to purchase, up to 12,500shares subject to the Company obtaining all necessary stockholder approvals to issue the shares to Keystone. The price of the shares purchased by Keystone under the ELOC is 90% of various volume-weighted average price (“VWAP”) and closing price-based formulae, and requires a waiver, should the selling price be below $ 2,000.00per share. As consideration for Keystone’s commitment to purchase shares of Common Stock pursuant to the Old Keystone Purchase Agreement, we issued an aggregate of 932shares of Common Stock to Keystone. During the nine months ended September 30, 2024, the Company sold 10,244shares for net proceeds of approximately $ 3.6million under the Keystone ELOC. The Company sought and received a